Answers are grounded in this paper and cite their sources.
Patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) early breast cancer (EBC) with high-risk clinicopathological features face an increased risk of recurrence. This study explored the evolving treatment landscape and clinical outcomes in patients with EBC using a nationwide database.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: